AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2500
- Registration Number
- NCT06268873
- Locations
- 🇻🇳
Research Site, Hochiminh city, Vietnam
Study of AZD0754 in Participants With Metastatic Prostate Cancer
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT06267729
- Locations
- 🇦🇺
Research Site, East Melbourne, Australia
A Retrospective Chart Review to Investigate Clinical Remission in Patients With Severe Asthma Treated With Biologics in the United Kingdom National Health Service
Recruiting
- Conditions
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 425
- Registration Number
- NCT06261567
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Observational Study Protocol: LIVER-R
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4490
- Registration Number
- NCT06252753
- Locations
- 🇸🇬
Research Site, Singapore, Singapore
A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT06245551
- Locations
- 🇷🇺
Research Site, Ulyanovsk, Russian Federation
Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations
Recruiting
- Conditions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1500
- Registration Number
- NCT06245837
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
A Study to Assess Multidomain Endpoints of an ECG Patch
Recruiting
- Conditions
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT06243029
- Locations
- 🇬🇧
Research Site, Leicester, United Kingdom
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 112
- Registration Number
- NCT06238466
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Brazilian Reality of Hepatocellular Carcinoma
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT06230328
- Locations
- 🇧🇷
Research Site, Vitoria, Brazil
Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2
- Registration Number
- NCT06231693
- Locations
- 🇧🇷
Research Site, São Paulo, Brazil
© Copyright 2024. All Rights Reserved by MedPath